| INTRODUCTION
Venous thromboembolism is a recognised complication of inflammatory bowel diseases (IBD). [1] [2] [3] It is associated with morbidity and mortality that are potentially avoidable with prophylaxis. 4 Thromboprophylaxis is not free of risk, cost or discomfort.
It is recognised that prophylaxis is justified by the size of thromboembolic risk among hospitalised inflammatory bowel disease patients, which leads to widespread acceptance that this should be routine. [5] [6] [7] [8] We demonstrated that the risk of venous thromboembolism is also increased in ambulant inflammatory bowel disease patients, and the risk is higher in periods of bowel inflammation. 9 Our work did not demonstrate any additional period in which prophylaxis may be justified.
However, we were unable to elucidate the precise time periods when inflammatory bowel disease patients were at high risk of thromboembolic events due to limitations of the data, and we had to estimate the dates of hospital admission and discharge from general practice records. 9 We have since been able to obtain primary care records (Clinical Practice Research Datalink), linked to hospital records (Hospital Episode Statistics), and this enabled us to re-examine this issue using methodology from other studies investigating the association between venous thromboembolism and diseases using linked data. [10] [11] [12] Over the same period, it has become standard practice to extend thromboprophylaxis in patients undergoing major surgery for abdominal or pelvic cancers to up to 28 days after surgery. 13 We have therefore revisited the question of when inflammatory bowel disease patients are at an increased risk of thromboembolic events, defining admission and surgery dates using hospital records, and have also examined the period after leaving hospital when the effect of extended prophylaxis may occur.
| MATERIALS AND METHODS

| Data sources
We identified a cohort of inflammatory bowel disease patients with a diagnosis of Crohn's disease, ulcerative colitis or indeterminate col- Clinical Practice Research Datalink (CPRD) is one of the world's largest databases of longitudinal primary care records. Over 600 practices, covering around 7% of the UK population, have been contributing data on primary care events such as consultations, symptoms and diagnoses, investigations and prescriptions. CPRD audits data from each practice and assigns an "up-to-standard" date, after which records are judged to be of acceptable standard for research. A primary care practice is designated as "up-to-standard" when the quality of the data it contributes meet the minimum quality criteria.
Patient records after the "up-to-standard" date should not contain any significant gaps in their data, and the recording of deaths or the date when patients left a practice is accurate. 14 These data are linked for a subset of practices to other data sources allowing enrichment of the data. The quality of data on inflammatory bowel disease and diagnoses of venous thromboembolism has also been validated externally. 
| Outcome event
The outcome event was the first record of pulmonary embolism Patients were considered at risk of the outcome from the later of the index date or the date our data began. They were no longer considered at risk after the end of data or after the first instance of the outcome, whichever was earlier.
| At-risk periods
We divided phases of inflammatory bowel disease activity as "acute"
(or "flare"), "chronic" or "in remission". An "acute" phase began with issuance of a new corticosteroid prescription or a record of inpatient admission with Crohn's disease (International Classification of Diseases, 10th revision: K50) or ulcerative colitis (K51) as the main diagnosis following a period of remission. Patients continuing to receive corticosteroids beyond the first 120 days after a flare had started (ie, the "acute" phase) entered a "chronic" phase, which lasted until 120 days after the last corticosteroid prescription. The remission period started 120 days after the last corticosteroid prescription or IBD-related hospital admission. 9 Hospitalisation status was classified into "in-patient", "after discharge" and "ambulatory". The "after discharge" period lasted for 6 weeks following the date when a patient left hospital. Though thromboembolic events that occur sooner after leaving hospital are more likely to be attributable to the in-patient stay, the "after discharge" period must also be long enough so that a reasonable number of events can accrue for analysis. Our choice of 6 weeks was a compromise between these requirements and any length from 28 to 90 days used by other authors.
| Statistical analysis
We estimated the ratio of occurrence (hazard ratios) of venous thromboembolism between inflammatory bowel disease and non-IBD patients in a Cox proportional hazards model, with adjustment for age, sex, body mass index (averaged over all the records of each patient), tobacco use, history of malignancy and previous thromboembolic events. Tobacco use was categorised as, from high to low, "current", "ex-smoker", "not current" or "unknown" based on the highest recorded level.
We further investigated the contribution of inflammatory bowel disease activity and in-patient stays to the risk of venous thromboembolism in time-varying Cox proportional hazards models, to incorporate temporal changes in inflammatory bowel disease severity and hospital use status, and in a self-controlled case series analysis, in which we used data from individuals who had a thromboembolic event and at different phases of inflammatory bowel disease activity. 19, 20 We illustrated temporal changes in the cumulative hazard of thromboembolic events, in which the risk of venous thromboembolism in each period was represented by the gradient of each curve. 21 In the self-controlled case series analysis, we examined the strength of association between an outcome, a thromboembolic event, and time-varying exposures such as different periods of hospital stays and inflammatory bowel disease activity. This analysis used records from patients who experienced a thromboembolic event during the observation period, and compared the probability that a thromboembolic event occurred in periods when patients were exposed (eg, during hospital stays) to unexpose (eg, while ambulatory). 19, 20 This approach estimates the change in the risk of venous thromboembolism in patients when their exposure status changes with time.
Analyses were carried out in Stata and in the R statistical language. were younger than non-IBD patients (mean = 59.4 years, 43.2% were 61-80 year-olds). Inflammatory bowel disease patients also had lower body mass indices (Table 1) . Patients with a thromboembolic event were also more likely to have a previous event: 20.5% had a previous thromboembolic event in inflammatory bowel disease patients, which was more than double the proportion in non-IBD patients (9.1%). The proportion of patients with a history of malignancy was similar for inflammatory bowel disease (16.6%) and non-IBD patients (14.2%) who did not have any thromboembolic events. In patients who had a thromboembolic event, 26.5% of inflammatory bowel disease patients and 30.8% of non-IBD patients had a history of malignancy.
| Overall risk of a thromboembolic outcome
The overall risk of venous thromboembolism in inflammatory bowel disease patients was 74% higher than in non-IBD patients (hazard ratio, HR = 1.74, 95% CI = 1.55-1.96) from Cox proportional hazards models (Table 2 and Figure 1 ). The risk of venous thromboembolism varied with inflammatory bowel disease activity: it rose to four times as high as in non-IBD patients (HR = 4.02, 95% CI = 3.08-5.25) during an acute episode, and fell slightly when the inflammatory process entered the chronic phase (HR = 3.71, 95% CI = 2.87-4.79). During remission, thromboembolism risk remained at 39% higher than in non-IBD patients (95% CI = 1.21-1.60). In inflammatory bowel disease patients, analysed using the self-controlled case series method to eliminate all time stable confounding, the thromboembolism risk during chronic phase was 2.64 times (95% CI = 1.76-3.96) the risk when in remission, which was similar to the risk of thromboembolism during the acute phase (rate ratio, RR = 2.37, 95% CI = 1.71-3.29) (Table 3 and Figure 2 ).
| During in-patient stays
The absolute risk of venous thromboembolism during an in-patient Figure 3 ). The risk of thromboembolism was similar between inflammatory bowel disease and non-IBD patients not undergoing any major surgery (HR = 1.13, 95% CI = 0.63-2.02), but very few thromboembolic events occurred in each of three phases of inflammatory bowel disease activity (Tables 2 and   3 ). In patients undergoing major surgery, the risk of thromboembolism was higher in inflammatory bowel disease patients than in non-IBD patients (HR = 2.43, 95% CI = 1.20-4.92).
| Within 6 weeks after discharge
The thromboembolism risk was similar between inflammatory bowel disease and non-IBD patients after major surgery (HR = 1.01, 95% CI = 0.67-1.52) and also after admissions not involving major surgery (HR = 1.03, 95% CI = 0.77-1.37) ( Table 2 ). The risk of thromboembolism was not found to vary with inflammatory bowel disease activity after leaving hospital (Table 3) .
| While ambulant
Inflammatory bowel disease patients were at a higher risk of venous thromboembolism than non-IBD patients while ambulant (HR = 1.71, 95% CI = 1.48-1.98) ( Table 2 Table 3 ).
| DISCUSSION
We have demonstrated that inflammatory bowel disease patients were at a higher risk of venous thromboembolism-74% greater than non-IBD patients (overall adjusted HR = 1.74, 95% CI = 1.55-1.96). Consistent with our previous study, thromboembolism risk was found to be raised when inflammatory bowel disease was active and remained so while ambulant, and the period of elevated risk not confined only to in-patient episodes. 9 We have also shown that the risk of thromboembolic events was higher during in-patient episodes involving major surgery, which persisted for a number of weeks after leaving hospital.
T 
| Strengths and weaknesses
This study has strengths and weaknesses inherent to the use of routinely collected data. Using anonymised data, we have forfeited the ability to verify the accuracy of individual patient's clinical records. This is not a major drawback since the exposure status (inflammatory bowel disease) central to our study and its outcome (venous thromboembolism) have been demonstrated to be reliably recorded in the data we used. 15, 16 The data we used are incomplete in some variables, and for example, completeness of data on body mass index and tobacco use (around 15% and 5% with unknown status) cannot be improved further and self-reported tobacco use history cannot be verified because of anonymisation. This misclassification and residual confounding may lead to biased estimation of their effects on the
T A B L E 2 Estimated hazard ratios, from time-varying Cox models, of the risk of a venous thromboembolic event (VTE) at different periods of inflammatory bowel disease (IBD) activity and hospitalisation, when compared to non-IBD patients in identical situations
VTE events Follow-up (person-years) Incidence rate (1000 p-y) Hazard ratio (adjusted) 95% CI
All periods combined and likewise, our finding that the risk of venous thromboembolism is connected to inflammatory bowel disease activity accords with our previous study and with another study showing many IBD-related thromboembolic events occur in periods of intense disease activity. 9, 23 We used corticosteroid prescription as a proxy for disease activity, and other studies have suggested a more direct role for corticosteroids. 24 Our estimation of thromboembolism risk in ambulatory patients with active inflammatory bowel disease is lower than in our previous study, perhaps suggesting bias from previous misclassification of at-risk periods. 9 We estimated hospital admission and discharge dates from general practice records previously, whereas we had accurate information from hospital data in this study. It may be possible that in-patient periods in our previous study were more periods. This may also explain why, contrary to the results from our previous study, the risks of thromboembolism in acute and chronic phases of inflammatory bowel disease appeared to be similar.
New findings from this study include the effect of surgery on the risk of venous thromboembolism and the prolonged at-risk period after leaving hospital. We are by no means the first to recognise patients undergoing surgery are at a greater risk of thromboembolic events among inflammatory bowel disease or non-IBD patients. Surgery has long been recognised as a risk factor irrespective of inflammatory bowel disease. 25 More specific data on surgery in inflammatory bowel disease patients are also available-the odds of thromboembolism associated with elective colectomy were 3.7 times and with emergency colectomy 5.3 times that in ulcerative colitis patients receiving medical therapy alone. 26 It is therefore unsurprising that inflammatory bowel disease patients undergoing major surgery had some of the highest thromboembolism risk during inpatient episodes and after leaving hospital. However, our findings on the effect of surgery on venous thromboembolism after leaving hospital are not entirely consistent with the recent literature. Surgical admission is not related to the risk of thromboembolic events after correcting for confounding factors in a recent case-control study that has included in-patient thromboprophylaxis data. 27 We have no access to data on in-patient prescription and are thus unable to exclude the possible effect of thromboprophylaxis. However since in-patient thromboprophylaxis is part of the standard care in both IBD-related surgical and non-surgical admissions, the differences we have found are unlikely to be attributable to this practice. 28 Thus, our finding of high risk of venous thromboembolism in the first 6 weeks after leaving hospital following surgery for inflammatory bowel disease is valid notwithstanding this limitation of our data.
| Prophylaxis against venous thromboembolism
Our aim was to estimate, more accurately, the absolute risk of venous thromboembolism in different phases of inflammatory bowel disease activity, with a view to better support decision-making of when thromboprophylaxis is likely to be appropriate. The risk of thromboembolic events increases to 1.5-3 times the background risk after air travel in the general population, 3-5 times during pregnancy and puerperium and 4-7 times in persons taking oral contraceptives. 29 The fourfold increase in thromboembolism risk associated with acute or chronic inflammatory bowel disease activity while ambulant (4.9 per 1000 person-years) would therefore not be a sufficient reason for routine prophylaxis against venous thromboembolism among inflammatory bowel disease patients.
The risk of thromboembolism is substantially higher in both inflammatory bowel disease and non-IBD patients while in hospital, especially after major surgery (close to 30 per 1000 person-years).
The current consensus is to offer prophylaxis to in-hospital inflammatory bowel disease patients until they are ambulant, and it is important to recognise much of the risk has been reduced by such prophylaxis. 4, [30] [31] [32] In recent years, there has been a growing body of evidence on the persistence of the risk of thromboembolism after leaving hospital for major surgery and the potential for a longer period of prophylaxis. Extension of thromboprophylaxis has been shown to be safe and efficacious, especially after surgery for colorectal cancer. [33] [34] [35] This has become routine practice and is now recommended in national guidelines. 13 We have found that the risk of a thromboembolic event persists after surgery in inflammatory bowel disease patients for some time after leaving hospital. This is also supported by another study showing an excess risk of venous thromboembolism in those undergoing emergency surgery. 36 The size of the risk of thromboembolism we found is consistent with other patients after major surgery, suggesting similar post-operative risks in inflammatory bowel disease patients and in patients undergoing surgery for colorectal cancer.
36-38
| CONCLUSION S
We found inflammatory bowel disease patients have a 1.75-fold increase in the risk of thromboembolism overall, and that the absolute risk is highest during hospital admissions especially after surgery.
We have confirmed patients outside hospital have a higher risk when their inflammatory bowel disease is active, but the size of the absolute risk does not warrant routine thromboprophylaxis. We have also shown that inflammatory bowel disease patients remain at high risk of thromboembolic events after leaving hospital for surgery, and their absolute risk is similar to other patients undergoing major surgery. Our findings suggest that the current focus on thromboprophylaxis in hospitalised inflammatory bowel disease patients is appropriate, but raises the question on whether it should be extended to the period after leaving hospital for inflammatory bowel disease patients as it is for colorectal cancer patients.
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